{rfName}
Pr

Indexed in

License and use

Icono OpenAccess

Citations

66

Altmetrics

Analysis of institutional authors

Bataller, AlexAuthor

Share

Publications
>
Article

Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax

Publicated to:Blood Advances. 8 (4): 927-935 - 2024-02-17 8(4), DOI: 10.1182/bloodadvances.2023011757

Authors: Bataller, Alex; Bazinet, Alexandre; Dinardo, Courtney D; Maiti, Abhishek; Borthakur, Gautam; Daver, Naval G; Short, Nicholas J; Jabbour, Elias J; Issa, Ghayas C; Pemmaraju, Naveen; Yilmaz, Musa; Montalban-Bravo, Guillermo; Takahashi, Koichi; Loghavi, Sanam; Garcia-Manero, Guillermo; Ravandi, Farhad; Kantarjian, Hagop M; Kadia, Tapan M

Affiliations

Abstract

Hypomethylating agents (HMAs) and venetoclax (Ven) represent the standard of care for patients with acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy. However, the European LeukemiaNet (ELN) risk classifications have been validated for patients treated with intensive therapy. In this study, we validate a recently proposed new molecular prognostic risk signature (mPRS) for patients with AML treated with HMAs and Ven. This classification allocated patients to favorable, intermediate (N/KRAS or FLT3-internal tandem duplication mutations), and lower (TP53 mutations) benefit groups. We retrospectively analyzed 159 patients treated with HMA and Ven. The mPRS classification allocated 74 (47%), 31 (19%), and 54 (34%) patients to the higher, intermediate, and lower -benefit groups, respectively. The overall response rate was 71% (86%, 54%, and 59% in the higher, intermediate, and lower -benefit groups, respectively). The median overall survival (OS) and event -free survival (EFS) times were 30 and 19 months, respectively, in the higher -benefit group; 12 and 8 months in the intermediate -benefit group; and 5 and 4 months in the lower -benefit group (P < .001). The C -index for OS and EFS was higher when stratifying patients according to mPRS classification than with the ELN 2022 classification. The 2 -year cumulative incidence of relapse was 35%, 70%, and 60% in the higher, intermediate, and lower -benefit groups, respectively (P = .005). The mPRS classification accurately segregated groups of patients with AML treated with HMA plus Ven. In these patients, N/KRAS and TP53 mutations appear to negatively affect outcomes; therefore, new treatment approaches are warranted.

Keywords

AmlBridged bicyclo compounds, heterocyclicFollow-upHumansLeukemia, myeloid, acutePrognosisProto-oncogene proteins p21(ras)Retrospective studiesStratificatioSulfonamidesVenetoclax

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Blood Advances due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2024 there are still no calculated indicators, but in 2023, it was in position 12/97, thus managing to position itself as a Q1 (Primer Cuartil), in the category Hematology.

Independientemente del impacto esperado determinado por el canal de difusión, es importante destacar el impacto real observado de la propia aportación.

Según las diferentes agencias de indexación, el número de citas acumuladas por esta publicación hasta la fecha 2025-06-06:

  • WoS: 28
  • Scopus: 38
  • OpenCitations: 16

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-06-06:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 54.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 51 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 65.15.
  • The number of mentions on the social network X (formerly Twitter): 74 (Altmetric).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.

Leadership analysis of institutional authors

This work has been carried out with international collaboration, specifically with researchers from: United States of America.

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: First Author (Bataller Torralba, Alex) .